Apigenin — Research Profile

No — apigenin is a single flavonoid compound found in chamomile, but chamomile contains many other active compounds including other flavonoids, terpenoids, and coumarins. Taking purified apigenin gives you the primary sleep-promoting compound in a standardized dose, while chamomile extract provides the full spectrum of chamomile compounds. Both approaches are valid; apigenin offers precision, while chamomile extract may benefit from synergistic effects.

In cell and animal studies, yes — Escande et al. (2013) showed apigenin inhibits CD38, the primary NAD+-consuming enzyme in mammalian cells, resulting in increased intracellular NAD+ levels. However, this effect has not been confirmed in human clinical trials at typical supplement doses (50mg). The NAD+ benefit should be considered a promising secondary effect rather than the primary reason to take apigenin.

The 50mg dose is widely used based on extrapolation from chamomile clinical trials ^[1] and was popularized by neuroscientist Andrew Huberman. Many users report subjective sleep improvement at this dose. However, no direct dose-ranging study of purified apigenin for sleep has been published. Some people may benefit from higher doses (up to 100mg), but caution is warranted given limited human dosing data. Start with 50mg and assess your response before increasing.

The two practical options are purified apigenin (usually capsules) and chamomile extract standardized to contain apigenin, and no head-to-head human bioavailability comparison exists between them. Apigenin is poorly water-soluble and has low oral absorption, which is why some products use enhanced-delivery formulations, though these have not been shown in people to improve any clinical outcome. Notably, the only form with direct human efficacy data is whole chamomile extract, not isolated apigenin.

Human evidence is limited: the only controlled clinical benefit tied to apigenin-containing material is a modest anxiolytic effect of chamomile extract in mild-to-moderate generalized anxiety disorder (a statistically significant but small reduction in anxiety scores over 8 weeks). The widely cited anticancer, anti-inflammatory, neuroprotective, and Alzheimer's benefits of isolated apigenin come entirely from animal and cell studies and have not been confirmed in people. Its popular use for sleep is not yet supported by any published human trial of the purified compound.

No clinically established daily dose exists for isolated apigenin, because dose-response trials of the purified compound in people have not been conducted; the commonly sold 50 mg pre-bed capsule reflects market convention rather than evidence that this amount is effective or optimal. The one human trial that used a defined apigenin quantity gave German chamomile extract standardized to 1.2% apigenin in 220 mg capsules (about 2.6 mg apigenin each, escalated to a maximum of five capsules per day, roughly 13 mg apigenin) - well below the 50 mg isolated dose and delivered within a whole-plant matrix, so it cannot fix an isolated-apigenin target either. A measurable apigenin intake therefore exists only for chamomile, and it does not validate any specific dose of the standalone supplement.

Apigenin is marketed mainly for nighttime use, taken 30-60 minutes before bed for its presumed calming effect, but timing has never been directly compared in a human study. For anxiety, the chamomile trial that showed benefit dosed throughout the day rather than only at night, so an evening-only schedule is an assumption carried over from its sleep positioning. Choose timing based on the effect you are after while recognizing there is no comparative evidence for one schedule over another.

There is no dedicated human safety dataset for isolated apigenin, so its side-effect profile is inferred from chamomile, in which adverse events in the anxiety trial were infrequent and similar to placebo. Because apigenin-rich chamomile belongs to the Asteraceae (daisy/ragweed) family, allergic reactions are the most clinically relevant risk in sensitive individuals. Drowsiness is plausible given its sedative positioning, though it has not been systematically quantified for the purified compound.

Apigenin inhibits CYP3A4 in laboratory (in vitro) assays, with reported IC50 values in the low-micromolar range (roughly 1.5-2.3 microM against human liver microsomes), and in rats it raised absorption of the chemotherapy drug paclitaxel dose-dependently in a manner attributed to inhibition of the P-glycoprotein transporter. Through these two pathways it could in theory increase blood levels of medications that are CYP3A4 or P-glycoprotein substrates - including some chemotherapy agents, certain statins, and various sedatives - though no human interaction study has confirmed a clinically significant effect. Anyone on narrow-therapeutic-index or CYP3A4/P-glycoprotein-sensitive drugs should therefore treat concentrated apigenin supplements with caution.

Apigenin mainly appeals to people seeking a mild, non-prescription option for sleep or everyday anxiety, but they should know the only supporting human evidence is a modest anxiety benefit from chamomile rather than proof for the isolated compound. It is a poor choice for anyone with a ragweed or daisy-family (Asteraceae) allergy, and it should be avoided or medically cleared by people taking chemotherapy or other CYP3A4/P-glycoprotein-sensitive medications given its interaction potential. Pregnant or breastfeeding individuals lack safety data for concentrated apigenin and are best steered away from it.

There is no human trial of isolated apigenin that measured an onset window, so any timeline is inferred rather than established. Its most popular use, calming/sleep support taken before bed, targets a same-night effect that has never actually been tested in people. The closest human data come from chamomile extract (apigenin's main dietary source), where anxiolytic separation from placebo emerged gradually over an 8-week generalized-anxiety trial rather than immediately.

Long-term safety of isolated apigenin supplements is not established, because no human study has tracked purified apigenin beyond a few weeks. The most relevant human safety signal is from chamomile extract, which was tolerated over 8 weeks in a generalized-anxiety trial with adverse-event rates comparable to placebo. Because apigenin inhibits drug-metabolizing enzymes in laboratory models, the main open question for chronic use is interaction potential rather than a documented organ-toxicity risk.

No upper limit or human toxicity threshold has been defined for apigenin, since dose-ranging studies in people do not exist. Animal studies have used doses far higher (scaled to body weight) than typical 50 mg supplements without acute toxicity, but that does not translate to a safe human ceiling. At high intakes the more realistic concern is enzyme- and transporter-mediated drug interactions rather than direct poisoning.

Apigenin is commonly stacked with other sleep aids such as melatonin, magnesium, or valerian, but additive sedation from these combinations has not been formally tested. A specific caution is that apigenin inhibits CYP3A4 and P-glycoprotein in laboratory and animal models, so pairing it with other botanical enzyme inhibitors could compound effects on how co-administered compounds are absorbed and cleared. There is no human combination-trial evidence to confirm either benefit or harm from these stacks.

There is no pharmacopeial standard for isolated apigenin, so check that the label states the actual apigenin content and purity (isolated products are often listed around 98%) rather than just a chamomile blend. Chamomile-derived products vary widely in how much apigenin they deliver, and apigenin content in the plant itself varies by cultivar and growing conditions. Third-party testing for identity and contaminants is the most useful assurance, since supplement-grade apigenin is not tightly regulated for potency.